Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
6.10
-0.32 (-4.98%)
At close: Aug 13, 2025, 4:00 PM
6.17
+0.07 (1.10%)
Pre-market: Aug 14, 2025, 8:04 AM EDT
Immatics Employees
As of December 31, 2024, Immatics had 682 total employees, including 554 full-time and 128 part-time employees. The number of employees increased by 147 or 27.48% compared to the previous year.
Employees
682
Change (1Y)
147
Growth (1Y)
27.48%
Revenue / Employee
$224,081
Profits / Employee
-$128,724
Market Cap
741.46M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMTX News
- 1 day ago - Immatics Announces Second Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 2 months ago - Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma - GlobeNewsWire
- 3 months ago - Immatics Announces First Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 4 months ago - Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting - GlobeNewsWire
- 4 months ago - Immatics N.V.: Trading Below Cash, But Not Without Reason - Seeking Alpha
- 5 months ago - Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewsWire
- 9 months ago - Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME - GlobeNewsWire
- 9 months ago - Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME - GlobeNewsWire